Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist

American Journal of Health-System Pharmacy

Volumn 64, Issue 23, 2007, Pages 2483-2487

  Kopp, Brian J ^a   Mrsan, Melinda ^b   Erstad, Brian L ^c   Duby, Jeremiah J ^d  

^a UNIVERSITY OF ARIZONA MEDICAL CENTER   (United States)

^b Christus Santa Rosa Healthcare   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d KAISER PERMANENTE   (United States)

Author keywords

Clinical pharmacists; Clinical pharmacy; Critical care; Economics; Hospitals; Interventions; Pharmaceutical services; Toxicity

Indexed keywords

CORTICOSTEROID;

ADRENAL INSUFFICIENCY; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG COST; ECONOMIC ASPECT; HEALTH CARE PERSONNEL; HUMAN; INTENSIVE CARE; MEDICAL INFORMATION; MEDICAL RECORD REVIEW; PATIENT CARE; PHARMACIST; PRIORITY JOURNAL; PROBABILITY; SEPTIC SHOCK; STRESS ULCER;

EID: 36749062403     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060674     Document Type: Article

References (17)

1. Strand LM, Morley PC, Cipolle RJ et al. Drug-related problems: their structure and function. DICP. 1990; 24:1093-7.
2. Winslade NE, Strand LM, Pugsley JA et al. Practice functions necessary for the delivery of pharmaceutical care. Pharmacotherapy. 1996; 16:889-98.
3. Pedersen CA, Schneider PJ, Santell JP et al. ASHP national survey of pharmacy practice in acute care settings: monitoring, patient education, and wellness - 2000. Am J Health-Syst Pharm. 2000; 57:2171-87.
4. Bond CA, Raehl CL, Patry R. Evidence-based core clinical pharmacy services in United States hospitals in 2020: services and staffing. Pharmacotherapy. 2004; 24:427-40.
5. Matuszewski KA, Vlasses PH. Survey results from academic health center intensive care units: considerations for departments of pharmacy. Clin Ther. 1995; 17:517-24.
6. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, hospital pharmacy staffing, and medication errors in United States hospitals. Pharmacotherapy. 2002; 22:134-47.
7. Schumock GT, Butler MG, Meek PD et al. Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy. 2003; 23:113-32.
8. Papadopoulos J, Rebuck JA, Lober C et al. The critical care pharmacist: an essential intensive care practitioner. Pharmacotherapy. 2002; 22:1484-8.
9. Nesbit TW, Shermock KW, Bobek MB et al. Implementation and pharmacoeconomic analysis of a clinical staff pharmacist practice model. Am J Health-Syst Pharm. 2001; 58:784-90.
10. Bjornson DC, Hiner WO, Potyk RP et al. Effect of pharmacists on health care outcomes in hospitalized patients. Am J Hosp Pharm. 1993; 50:1875-84.
11. Leape LL, Cullen DJ, Dempsey-Clapp M et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999; 282:267-70.
12. Overhage JM, Lukes A. Practical, reliable, comprehensive method for characterizing pharmacists' clinical activities. Am J Health-Syst Pharm. 1999; 56:2444-50.
13. Bates DW, Spell N, Cullen DJ et al. The costs of adverse drug events in hospitalized patients. JAMA. 1997; 277:307-11.
14. Cicchetti DV, Feinstein AR. High agreement but low kappa: II. Resolving the paradoxes. J Clin Epidemiol. 1990; 43:551-8.
15. Byrt T, Bishop J, Carlin JB. Bias, prevalence and kappa. J Clin Epidemiol. 1993; 46:423-9.
16. Chaung LC, Sutton JD, Henderson GT. Impact of a clinical pharmacist on cost saving and cost avoidance in drug therapy in an intensive care unit. Hosp Pharm. 1994; 29:215-8.
17. Devlin JW, Holbrook AM, Fuller HD. The effect of ICU sedation guidelines and pharmacist interventions on clinical outcomes and drug cost. Ann Pharmacother. 1997; 31:689-95.